U.S. flag

An official website of the United States government

NM_000527.5(LDLR):c.910G>A (p.Asp304Asn) AND not provided

Germline classification:
Pathogenic (2 submissions)
Last evaluated:
Jun 14, 2022
Review status:
2 stars out of maximum of 4 stars
criteria provided, multiple submitters, no conflicts
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000985772.14

Allele description [Variation Report for NM_000527.5(LDLR):c.910G>A (p.Asp304Asn)]

NM_000527.5(LDLR):c.910G>A (p.Asp304Asn)

Gene:
LDLR:low density lipoprotein receptor [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
19p13.2
Genomic location:
Preferred name:
NM_000527.5(LDLR):c.910G>A (p.Asp304Asn)
Other names:
D283N; FH Denver 2; NM_000527.5(LDLR):c.910G>A
HGVS:
  • NC_000019.10:g.11107484G>A
  • NG_009060.1:g.23104G>A
  • NM_000527.5:c.910G>AMANE SELECT
  • NM_001195798.2:c.910G>A
  • NM_001195799.2:c.787G>A
  • NM_001195800.2:c.406G>A
  • NM_001195803.2:c.529G>A
  • NP_000518.1:p.Asp304Asn
  • NP_000518.1:p.Asp304Asn
  • NP_001182727.1:p.Asp304Asn
  • NP_001182728.1:p.Asp263Asn
  • NP_001182729.1:p.Asp136Asn
  • NP_001182732.1:p.Asp177Asn
  • LRG_274t1:c.910G>A
  • LRG_274:g.23104G>A
  • LRG_274p1:p.Asp304Asn
  • NC_000019.9:g.11218160G>A
  • NM_000527.4:c.910G>A
  • P01130:p.Asp304Asn
  • c.910G>A
Protein change:
D136N; ASP283ASN
Links:
LDLR-LOVD, British Heart Foundation: LDLR_001861; UniProtKB: P01130#VAR_005355; OMIM: 606945.0008; dbSNP: rs121908030
NCBI 1000 Genomes Browser:
rs121908030
Molecular consequence:
  • NM_000527.5:c.910G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001195798.2:c.910G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001195799.2:c.787G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001195800.2:c.406G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001195803.2:c.529G>A - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Synonyms:
none provided
Identifiers:
MedGen: C3661900

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV001134272Quest Diagnostics Nichols Institute San Juan Capistrano
criteria provided, single submitter

(Quest Diagnostics criteria)
Pathogenic
(Feb 5, 2019)
unknownclinical testing

PubMed (19)
[See all records that cite these PMIDs]

SCV002028774GeneDx
criteria provided, single submitter

(GeneDx Variant Classification Process June 2021)
Pathogenic
(Jun 14, 2022)
germlineclinical testing

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineyesnot providednot providednot providednot providednot providedclinical testing
not providedunknownunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Mutation analysis in familial hypercholesterolemia patients of different ancestries: identification of three novel LDLR gene mutations.

Callis M, Jansen S, Thiart R, de Villiers JN, Raal FJ, Kotze MJ.

Mol Cell Probes. 1998 Jun;12(3):149-52.

PubMed [citation]
PMID:
9664576

The molecular basis of familial hypercholesterolemia in The Netherlands.

Fouchier SW, Defesche JC, Umans-Eckenhausen MW, Kastelein JP.

Hum Genet. 2001 Dec;109(6):602-15. Epub 2001 Nov 9.

PubMed [citation]
PMID:
11810272
See all PubMed Citations (19)

Details of each submission

From Quest Diagnostics Nichols Institute San Juan Capistrano, SCV001134272.4

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (19)

Description

The frequency of this variant in the general population, 0.00012 (3/24946 chromosomes, http://gnomad.broadinstitute.org), is consistent with pathogenicity. In the published literature, the variant was identified in multiple individuals affected with hypercholesterolemia (PMID: 11810272 (2001), 12436241 (2002), 21418584 (2011), 22698793 (2012), 23064986 (2012), 24507775 (2014), 33740630 (2021), 34037665 (2021)). The variant has also been reported as compound heterozygous with another pathogenic variant in children with a severe presentation (PMID: 27678436 (2016), 30795984 (2019)). Functional studies of homozygous cultured fibroblasts showed a retention of only 5-15% LDLR activity (PMID: 1301956 (1992)). Based on the available information, this variant is classified as pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1unknownunknownnot providednot providednot providednot providednot providednot providednot provided

From GeneDx, SCV002028774.3

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided

Description

Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Published functional studies demonstrate significantly reduced LDL receptor activity compared to wild type (Hobbs et al., 1990; Hobbs et al., 1992); Also known as FH Denver-2 and p.D283N; This variant is associated with the following publications: (PMID: 2318961, 12436241, 31447099, 25637381, 25487149, 24507775, 2088165, 9664576, 11810272, 17094996, 21418584, 22698793, 34037665, 30795984, 1301956, 33740630, 32719484)

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineyesnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Nov 3, 2024